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Objectives To determine the incidence of inlet patch (IP) and to assess the clinical and pathological features, role
of the diagnostic workup in treatment decision making, efficacy of medical and endoscopic therapy, and natural
history in a pediatric population.
Study design Consecutive patients aged <18 years (n = 1000) undergoing esophagogastroduodenoscopy were
enrolled prospectively. Biopsy specimenswere obtained from IPs and the proximal and distal esophagus, stomach,
and duodenum.Multichannel intraluminal impedance and pHmonitoring (MII-pH) was performed in all symptomatic
patients. Symptomatic patients were treated with proton pump inhibitors for 8 weeks, and IP ablation by argon
plasma coagulation (APC) was performed in unresponsive patients.
Results The endoscopic incidence of IP was 6.3%, with a cumulative missing rate of 5.8%. Thirty-five of the 63
patients (56%) were asymptomatic, 11 (17%) had symptoms clearly related to the underlying digestive disorder,
and 17 (27%) had chronic IP-related symptoms. MII-pH was positive in 10 of the 28 symptomatic patients. All 17
patients with IP-related symptoms were unresponsive to proton pump inhibitors and were treated with APC, and
all had achieved complete remission by the 3-year follow-up. Patients with underlying disorders were successfully
treated with medical therapy, and asymptomatic patients remained symptom-free, with no endoscopic or histolog-
ical changes seen at the 3-year follow-up.
Conclusion IP is an under-recognized cause of symptoms in children with unexplained esophageal and respira-
tory symptoms. MII-pH and bioptic sampling are needed to exclude entities mimicking IP symptoms and to direct
therapy. APC is safe and effective for treating IP-related symptoms. (J Pediatr 2016;-:---).
A
n inlet patch (IP) is a salmon-colored, velvet-appearing, distinct area of heterotopic gastric mucosa typically located in the
proximal esophagus just distal to the upper esophageal sphincter. It is usually a single lesion but can bemultiple, ranging in
size from a few millimeters to >5 cm.1-3
The endoscopic-detected incidence of IP ranges from 0.1% and 10% in published studies.1,4-6 The true incidence may be
underestimated; in daily practice, IP is often missed during routine endoscopy. This might be related to the fact that the lower
part of the esophagus is more often in the focus of the endoscopist, owing to the frequent pathological findings in this area.5,7,8
Although generally asymptomatic, the presence of IP has been associated with laryngopharyngeal symptoms (ie dysphagia,
laryngospasms, hoarseness, globus throat discomfort, and chronic cough), likely related to acid production.4,9-13 IPs also have
been linked to complications including esophageal strictures, tracheoesophageal fistula, ulcerations, bleeding, and perfora-
tion.14-18 Furthermore, in an autopsy study of a pediatric population, the presence of an IP was associated with unexplained
death; the authors speculated that pulmonary aspiration of esophageal contents may cause death in some of these children.19
IPs are also potential sites for Helicobacter pylori infection.18,20 In addition, Barrett esophagus and adenocarcinoma within
IPs have been reported in adults, proving its potential, albeit rare, malignant progression.21-32
To date, only a few studies on IP in the pediatric population have been published, most of which are in case report form and
limited by their small sample size and retrospective design.10,11,33-38 The aims of the present prospective study were to assess: (1)
IP in a pediatric population in which the endoscopist is sensitized to search for this entity; (2) the associated clinicopathologicalFrom the 1Pediatric Unit, Orvieto Hospital, Orvieto, Italy;
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APC Argon plasma coagulation
AR Acid reflux
EGD Esophagogastroduodenoscopy
EoE Eosinophilic esophagitis
GERD Gastroesophageal reflux disease
IP Inlet patch
MII-pH Multichannel intraluminal impedance and pH monitoring
PPI Proton pump inhibitor
RSI Reflux symptom index
SAP Symptom association probability
SI Symptom index
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THE JOURNAL OF PEDIATRICS  www.jpeds.com Volume-features of IP; (3) the role of the diagnostic workup in treat-
ment decision making; (4) the efficacy of medical and endo-
scopic therapy; and (5) the natural history of IP.
Methods
Consecutive patients aged <18 years (n = 1000; 621 females)
undergoing esophagogastroduodenoscopy (EGD) for
various indications were prospectively assessed for the pres-
ence of IP between January 2011 and December 2012 at the
Pediatric Gastroenterology Units of the University of Rome
and University of Bologna. Patients who underwent endos-
copy for such indications as urgent, interventional, capsule
placement, enteroscopy, and systemic disorders (eg, Sj€ogren
syndrome, scleroderma) were excluded. The appropriate
Institutional Ethical Committees approved the study design.
Written informed consent was obtained from all parents, and
children when applicable, after they received a thorough
explanation of the research protocol.
Before EGD, all patients were carefully questioned about
symptoms experienced within the previous month using a
self-administered 9-item reflux symptom index (RSI).39 Pa-
tients graded the severity of each item from 0 (none) to 5 (se-
vere problem). Clinical response was defined as a reduction
in clinical score of at least 3 points for each symptom.
Endoscopic Procedures
All EGD procedures were performed under general anes-
thesia by an experienced endoscopist using a video gastro-
scope (GIF-180; Olympus, Hamburg, Germany). During
the procedure, the esophagus was carefully surveyed, with
particular attention to the area of the upper esophageal
sphincter. This area was best examined by slowly with-
drawing the endoscope, with repeated short inflations while
rotating the instrument.
IPs were identified as patches covered with salmon-red
mucosa distinguishable from surrounding grayish-pearl–
colored esophageal mucosa by well-defined margins
(Figure 1, A). Each IP was measured by comparing it with
the length of the metallic tip of the biopsy forceps (5 mm).Figure 1. A, Typical endoscopic appearance of IP. B, IP treatme
treatment.
2In patients with multiple patches, the sizes of all patches
were summed. Reflux esophagitis and Barrett esophagus
were surveyed and classified according to the Los Angeles
classification system40 and the Praque C & M criteria,41
respectively. Hiatal hernia was considered when the
maximum length of the gastric mucosal folds above the
gastroesophageal junction exceeded 20 mm.
Histopathological Assessment
At least 2 biopsy specimens were obtained from each IP using
disposable endoscopy biopsy forceps (EndoJaw FB 230V;
Olympus). Biopsy specimens were also obtained from the
proximal and distal esophagus, fundus, antrum, corpus,
and duodenum of the patients with an IP. All biopsy speci-
mens were blindly reviewed by a single pathologist. The squa-
mous mucosa was examined for changes of reflux
esophagitis,42 and the columnar mucosa was examined for
the presence and degree of inflammation and/or intestinal
metaplasia according to the modified Sydney classification
system.43 IP mucosal type was classified based on the pres-
ence of parietal and chief cells as antral type, fundic type,
or transitional type. The presence of H pylori was evaluated
using hematoxylin and eosin and Giemsa staining in the IP
and the gastric mucosa.Multichannel Intraluminal Impedance and pH
Monitoring
The presence of gastroesophageal reflux or IP-related acid
production was assessed using multichannel intraluminal
impedance and pH monitoring (MII-pH). For ethical rea-
sons, MII-pH was performed only in symptomatic patients
with IP.
The procedure was performed with a combined MII-pH
flexible catheter (Covidien-Medtronic, Minneapolis, Minne-
sota) with 8 impedance rings (representing 6 impedance chan-
nels) and 2 antimony pH sensors. The distal pH sensor was
located at 4.5 cm from the catheter tip, and the proximal pH
sensor was located 15 cm from the distal sensor. The 6 imped-
ance channels were located in the MII-pH probe at -2, 0, 2, 4,
13, and 15 cm from the distal pH sensor. The probe was thennt with APC. C, Endoscopic findings at the end of the APC
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was placed at 87%of the nares–lower esophageal sphincter dis-
tance (Strobel formula)44 and verified with fluoroscopy to be
at 2 vertebral bodies above the diaphragm. The catheter was
connected to a data recorder (Digitrapper pH-Z; Covidien-
Medtronic), and data were analyzed with dedicated software
(AccuView 5.2; Covidien-Medtronic). Tracings (meal
included) were also reviewed manually.
The following MII-pH variables were analyzed: total num-
ber of reflux episodes, number of acid reflux (AR) episodes,
number of weakly AR and weakly alkaline reflux episodes,
percentage of recording time with a pH <4 (RSI), number
of proximal reflux episodes, number of episodes of long
duration (>5 minutes), number of proximal acid-
independent episodes, symptom index (SI), and symptom
association probability (SAP).45,46
Acid secretion from IP was defined as any recording of pH
<4 by the proximal sensor that was not preceded by a
recording of pH <4 by the distal sensor. Such episodes are
termed “acid-independent” episodes. SI and SAP were calcu-
lated for AR, weakly AR, and alkaline reflux and were consid-
ered positive at scores of $50% and >95%, respectively.45,46
TheMII-pH analysis was considered abnormal at an RSI of
>5% or an SI of $50% or SAP of >95% for each symptom.
Medical, Endoscopic Therapy, and Follow-up
Regardless of the MII-pH results, all symptomatic patients
were treated with a proton pump inhibitor (PPI) for 8 weeks
(omeprazole 2 mg/kg twice daily, not to exceed 60 mg/day).
Ablation of the lesions by argon plasma coagulation (APC)
was proposed to patients unresponsive to PPI.
Each APC procedure was performed by 1 of 3 experienced
endoscopists using a gastrointestinal argon plasma system
(APC 300; ERBE Elektromedizin, T€ubingen, Germany) at a
power setting of 60 W and an argon flow of 2 L/min. A mu-
cosectomy cap was fitted at the distal tip of the endoscope
to improve the view and decrease the risk of damage to sur-
rounding squamous epithelium.35,47,48 The procedure aimed
to completely ablate all IPs in a single session (Figure 1, B
and C).
Symptoms were reevaluated at 3 months after APC treat-
ment, with a follow-up endoscopy performed to check for
potential side effects (eg, stricture formation) and complete-
ness of ablation. All patients were followed with telephone in-
terviews at 6, 12, 24, and 36 months after enrollment. An
endoscopic control was proposed to all patients with IP at
3 years after the first endoscopy.
Statistical Analyses
Demographic characteristics are reported as descriptive sta-
tistics: quantitative parameters are expressed as
mean  SD, and qualitative parameters as absolute and rela-
tive frequencies. Symptom incidence was compared between
the 2 groups using the Fisher exact test. Comparisons of
continuously scaled variables were performed using the para-
metric independent-samples t test. If assumptions for proper
application of the parametric t test (ie, normality and/orEsophageal Inlet Patch: An Under-Recognized Cause of Symptohomogeneity of variance) were violated, then the nonpara-
metric Mann-Whitney U test was performed. The statistical
significance was set at a P value < .05 (2-tailed test). All sta-
tistical analyses were conducted using SPSS version 19.0
(IBM, Armonk, New York).Results
IPs were endoscopically found and biopsy-confirmed in 63 of
the 1000 consecutive enrolled children, for an incidence of
6.3%. The study cohort comprised 37 females and 26 males,
with a median age of 12 3.5 years (range, 4-17 years). Inter-
estingly, 19 of the IPs were detected in a group of 323 children
who underwent previous EGD (performed by another endo-
scopists than the endoscopist involved in the present study),
with a cumulative missing rate of 5.8%. There was no signif-
icant difference in the missing rate between the symptomatic
patients and the asymptomatic patients (P = .36).
At endoscopy, a single IP was identified in 58 patients, and
multiple IPs were detected in 5 patients. The IPs were located
just distal to the upper esophageal sphincter and had amedian
size of 13.3 6 mm (range, 5-25 mm). There was no correla-
tion between IP size and presence/absence of symptoms.
Two cases were associated with H pylori erosive gastritis
without synchronous colonization of the IP. Three patients
had endoscopic findings suggestive of eosinophilic esophagi-
tis (EoE), which was confirmed on histological examination.
No patient had erosive esophagitis, Barrett esophagus, or
hiatal hernia.
Histology revealed that 26 of the 63 patients had fundic
type mucosa in the IP, 17 had antral type mucosa, and 13
had both antral and fundic typemucosa. Five patients had in-
testinal metaplasia in the IP; 3 of these patients had IP-related
symptoms and the other 2 were asymptomatic. Mild to mod-
erate chronic inflammation was seen in 7 patients. There was
no correlation between the degree of inflammation and the
presence or absence of symptoms. No patients exhibited
H pylori infection or any dysplastic changes. EoE was diag-
nosed in 4 patients, 1 of whom had a normal endoscopic
mucosal appearance.
Thirty-five of the 63 patients (56%) were asymptomatic,
and IP was an incidental finding. The clinical indications
were celiac disease in 11 patients, ulcerative colitis in 9,
Crohn’s disease in 13, and Peutz-Jeghers syndrome in 2.
Eleven of the 63 patients (17%) had symptoms clearly
related to the underlying digestive disorder: EoE in 3 patients,
H pylori infection in 2, and gastroesophageal reflux disease
(GERD) in 6 (in 2 as a consequence of esophageal atresia
repair). This was confirmed by complete clinical remission
with specific disease-directed therapy.
Seventeen of the 63 patients (27%) had chronic unex-
plained symptoms unresponsive to specific therapy,
including dysphagia and odynophagia in 2 patients,
dysphagia and pyrosis in 3, dysphagia in 2, globus sensation
and sore throat in 3, globus sensation and hoarseness in 1,
chronic cough in 4, and laryngospasm in 2.ms in Children 3
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No acid-independent episodes of secretion from the IP were
detected.
Clinical Outcomes and Management of
Symptomatic Patients
Among the 17 patients with persistent symptoms, 1 patient
with EoE (typical endoscopic and histological finding),
dysphagia, and pyrosis had persistent symptoms despite a
complete histological remission with oral topical steroid
plus PPI therapy negative MII-pH results. Four patients
with a MII-pH–based diagnosis of GERD (1 patient with
globus sensation and hoarseness, 2 patients with chronic
cough, and 1 patient with laryngospasms) had persistent
symptoms despite therapy with omeprazole 2 mg/kg and a
second MII-pH performed during the course of PPI therapy
showing good acid control with no correlation between
symptoms and AR/weakly AR/nonacid reflux events. Twelve
symptomatic patients with isolated IP had persistent symp-
toms despite therapy with omeprazole 2 mg/kg for 8 weeks.
All 17 patients with persistent symptoms were treated with
APC. Endoscopic follow-up performed 3 months after APC
showed complete IP eradication in all patients in the absence
of complications.
Natural History
Twelve of the 17 patients treated with APC were asymptom-
atic at the 3-year clinical follow-up. The patient with EoE
required a cycle of standard therapy with satisfactory clinical
response and 4 patients with GERD (detected by MII-pH)
required PPIs on demand. Endoscopic follow-up after 3 years
revealed no residual or recurrent IP lesions in any patients.
The 11 patients with an underlying disorder were treated
with standard therapy, and all exhibited a satisfactory clinical
response. Endoscopic follow-up performed in all but 2 of the
patients at 3 years did not reveal any endoscopic or histological
changes. The 2 patients lost to follow-up hadHpylori infection
and refused repeat endoscopy, and were available only for
clinical follow-up (Figure 2; available at www.jpeds.com).
Thirty-five asymptomatic patients continued to be
symptom-free at the 3-year follow-up. Endoscopic follow-
up was available for only 25 of these patients. Ten patients
with celiac disease refused repeat endoscopy and were avail-
able only for clinical follow-up. No endoscopic or histologi-
cal changes were evident in any of these patients.
Discussion
Traditionally considered a nonpathological incidental finding,
IP has now been identified as the possible cause of unex-
plained digestive and respiratory symptoms, such as chronic
cough, laryngospasm, sore throat, globus pharyngeus,
dysphagia, hoarseness, and vocal cord dysfunction,2-7,9-12 at
least in in a subgroup of patients. Moreover, case reports
have shown that IP can play a role in the development of
severe complications, such as webs, strictures, ulcers,
perforation, fistulas, and adenocarcinoma.14-324The endoscopic incidence of IP in pediatric patients ranges
from 0.03% to 1.4% in retrospective studies.33,34 The sole pro-
spective pediatric study, performed in 407 children, showed a
incidence of 5.9%,11 similar to that found in our study popu-
lation. We found a missing rate of 5.8% in a selected group of
children who had undergone previous EGD. These data
confirm results reported by Azar et al8 in adults showing a
higher incidence of IP when the operator is aware of the entity.
Taken together, these data suggest that IP is a frequently un-
recognized entity that has received little attention in the pedi-
atric literature. Thismay be due to technical difficulties related
to endoscopic evaluation of the proximal esophagus. Data
from adult studies show that narrow-band imaging increases
the detection of IP by approximately 3-fold compared with
standard white light endoscopy.49,50
In our series, we did not find associations between IP and
erosive esophagitis, Barrett esophagus, or hiatal hernia, but
did find an association between IP and EoE. This intriguing
finding, although related to the high incidence of EoE in
the subjects followed in our center (18 new EoE diagnoses
in the study period, and a total of 44 patients with EoE under
follow-up), confirms the importance of careful examination
and appropriate biopsy sampling of the entire esophagus in
children undergoing upper endoscopy for dysphagia.
In our cohort, we found a predominant fundic type mu-
cosa, with no correlation between inflammation degree and
symptoms. In contrast to previous reports,18,20,33,34 we found
no evidence ofH pylori colonization. We identified intestinal
metaplasia in the IP in 5 patients, 2 of whom were asymp-
tomatic. Given the preneoplastic nature of this abnormality
in adults,21,25-32 our data support the relevance of IP biopsy
sampling to identify patients requiring endoscopic and histo-
logical surveillance. Furthermore, future studies based on
MII-pH, immunohistochemical, and molecular analyses in
all patients (ie, symptomatic and asymptomatic) might
explain the development of metaplasia in IP.
An important challenge for clinicians is to determine
whether IP is associated with symptoms. Compared with
healthy controls, both children and adults with IP have a
higher incidence of digestive and respiratory symptoms.1,3-
7,9-12 This led us to hypothesize that acid secretion plays a
role in symptom generation and such complications as stric-
ture, ulceration, and fistulas.13,51,52 Acid secretion from the
IP was documented in only a small proportion of symptom-
atic patients, however.13,53 In this study, we did not find any
acid-independent episodes related to IP, suggesting that
mechanisms other than acid-induced injury are involved in
symptom generation.
Approximately 56% of our subjects were asymptomatic (ie,
IP considered an incidental finding), 17% had symptoms
related to another underlying disorder, and 27% had IP-
related symptoms. Among the subjects with non–IP-related
symptoms, histological analysis and MII-pH monitoring
identified 3 cases of EoE, 2 cases of H pylori infection, and 6
cases of GERD, and IP was an incidental finding in all of these
subjects. Among the subjects with IP-related symptoms, we
identified overlap with EoE in 1 and overlap with GERD inDi Nardo et al
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tained only after IP ablation with APC, suggesting IP as the
main cause of the symptoms. In all of the symptomatic cases,
an extensive diagnostic workupwas essential to correctly iden-
tify the role of IP in symptom generation, thereby avoiding
unnecessary treatments (eg, surgical treatment for GERD,
APC ablation for IP).
There are no standardized treatment strategies for IP.
Treatment should be recommended to symptomatic patients
and may include pharmacologic therapy with PPIs or H2 re-
ceptor antagonists, complete endoscopic mucosal resection,
APC, and dilatation of strictures.1,15-18 Only a few previous
case reports have suggested the use of PPIs in patients with
history of laryngopharyngeal symptoms and IP in this region.
Unfortunately, no MII-pH studies were performed in these
patients, and for this reason we cannot exclude the possibility
of GERD overlap. In our study, 6 of 10 children with IP and
pathological MII-pH monitoring suggestive of GERD were
successfully treated with PPIs, and in the other 4 children,
MII-pH was useful in directing therapy toward IP ablation.
A positive effect of APC endoscopic ablation has been
demonstrated in adults with IP-related symptoms.48 This
approach was described in 3 pediatric cases as well, confirm-
ing the safety and efficacy of this technique,35 although large
and long-term follow-up studies are lacking. Here we report
the safety and efficacy of APC in 17 patients with IP-related
symptoms, who remained asymptomatic at 3-year follow-
up in the absence of endoscopic recurrence.
In conclusion, IP is an under-recognized cause of symp-
toms and should be suspected during endoscopic examina-
tion of children with unexplained esophageal and
respiratory symptoms. MII-pH and bioptic sampling of
both IP and esophageal mucosa aid in the exclusion of other
entities potentially responsible for symptoms and in the
choice of appropriate therapeutic management strategies. n
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